· 8 min read
Safety Risk Management, a Framework for Developing and Implementing Rems Modifications and Revisions
Rapidly evolving safety risk management processes increasingly dictate drug approval and post-marketing surveillance1. To meet FDA requirements of developing and implementing changes to risk-evaluation and mitigation strategies (REMS), and to streamline this complicated process, we have detailed a framework of key concepts, standards and submission procedures.
In 2007, the FDA Amendments Act (FDAAA), which amends the Federal Food, Drug and Cosmetics Act (FFDCA) to include post-market safety activities in the process for the review of human drug applications or supplements, introduced REMS to assure safe use of certain drugs. As defined by the FDA, “A REMS is a required risk management plan that uses tools beyond the prescribing information (the package inserts) to ensure that all benefits of certain drugs outweigh their risks.” (U.S. Food and Drug Administration, 2019, p. 2). Without REMS, some drugs could not be approved because of high safety risks. Prior to the REMS programs, a few products used risk minimization action plans (RiskMAPs) to the same end2. REMS supersedes RiskMAPs. The most extensive components of a REMS program are elements to assure safe use (ETASU), developed to mitigate specific and serious risks. Examples of common ETASU include:
- Prescribing physicians require more training or certification (e.g. to mitigate risk of severe allergic reaction)
- Patient monitoring for evidence of safe-use conditions (e.g. liver function monitoring to mitigate risk of liver damage and pregnancy screening with a negative result to mitigate risk of severe birth defects)
- Required enrollment in patient registry
Safety measures of a REMS are unique to a drug’s associated safety risks. The FDA can require a REMS at any time, pre- or post- approval, and a REMS can be required for a single drug, or for a class of drugs. While the FDA is responsible for reviewing and approving REMS programs, sponsors are responsible for developing them. When deciding if a REMS is needed, consider the following factors3:
- Population size
- Seriousness of the disease
- Expected benefit
- Expected treatment duration
- Seriousness of known or potential adverse events
- Novelty of the drug
REMS Revisions, Minor Modifications and Major Modifications
When new safety information becomes available, changes to a REMS may be proposed to ensure that a drug’s risk-to-benefit ratio is acceptable. Changes to a REMS may also be proposed to reduce the burden on health care professionals of complying with the REMS. Changes to a REMS are categorized as REMS revisions, minor REMS modifications and major REMS modifications, depending on the degree of potential effect on serious risk, safe use and the actions necessary to comply with the REMS4. Each REMS category has different submission criteria and regulatory action requirements (see the table below).
Submissions Criteria, Examples and Regulatory Action for REMS Changes4
Essentials to Submitting and Implementing Proposed REMS Changes4
- If needed, seek advice from the FDA before submitting a proposed REMS modification.
- Include a REMS history outlining all changes made to the REMS since original approval.
- For minor and major modifications, except for FDA-required submissions, submit adequate rationale for the change. Detailed instructions for specific causes are provided in the FDA’s Guidance for Industry, Risk Evaluation and Mitigation Strategies: Modifications and Revisions (U.S. Food and Drug Administration, 2019, p.13).
- REMS revisions can be implemented immediately upon FDA receipt of the submission; no action is required from the FDA for this type of change.
- Minor modifications can be implemented 30 days after FDA receipt of the submission; however, the FDA has 60 days from receipt of the submission to review and act on minor modifications; therefore, changes are not considered final until FDA approval.
- Major modifications cannot be implemented until the FDA approves the proposed changes. The FDA has 180 days after receipt of the submission to review and act on proposed major modifications, with the exception of major modifications due to safety labeling changes that are considered conforming. In this instance, the FDA has 60 days after safety labeling changes are approved to review and act on the proposed major modifications. The 180-day time frame, following approval of the safety labeling changes, applies to major modifications due to safety label changes that are not considered conforming.
- REMS for NDAs and BLAs require assessment of the effectiveness of its safety measures at 18 months, three years and seven years after a REMS is approved, documented in a timetable to be included in the submission application. Assessments inform sponsors of the necessity of continuing a REMS program or modifying it.
Challenges to the Development and Implementation of REMS
- Developing and implementing a REMS program is time-consuming and costly, which affects sponsors, health care providers and patients.
- No two REMS programs are alike; each has different requirements and challenges.
- Added REMS requirements can unduly burden patients and providers.
- Recently published FDA draft guidances direct sponsors through the development of a REMS assessment plan and the execution of REMS assessment surveys, but these tasks remain difficult and intimidating.
Did you know that our safety risk management experts have been successfully submitting REMS programs and changes to the U.S. FDA since the program’s start in 2007? Our safety and pharmacovigilance team can take your product through even the most complicated REMS program changes.
Challenges to REMS Development and Implementation Due to a Public Health Emergency (COVID-19)5
During a public health emergency (PHE), the FDA may impose temporary policies for certain REMS requirements. To ensure that timely response efforts meet patient needs in such situations, health care professionals, sponsors, regulators and other relevant parties should closely monitor FDA announcements and communicate with the FDA if needed.
In March 2020, specific to the COVID-19 pandemic, the FDA issued a new guidance addressing completion of REMS program ETASU requirements that may negate public health interventions for self-isolation and quarantine. This guidance states that laboratory testing or imaging studies required by some REMS can put patients and the public at risk of COVID-19 transmission and advises that “healthcare providers prescribing and/or dispensing these drugs should consider whether there are compelling reasons not to complete these tests or studies during the PHE, and use their best medical judgment in weighing the benefits and risks of continuing treatment in the absence of laboratory testing and imaging studies.” (U.S. Food and Drug Administration, 2020, p. 7). The guidance indicates that these accommodations should be documented and summarized in the REMS Assessment Report.
As information becomes available on COVID-19 and safety risk management, other temporary policies for certain REMS requirements may arise.
We cannot over-emphasize the importance of safety risk management. Regulators have expanded submission requirements to include REMS programs for certain high-risk products to maintain patient safety, and sponsors must keep up with the rapidly evolving changes.
To navigate complex REMS requirements and challenges, let our safety and pharmacovigilance experts plot your REMS strategy course. We have extensive experience designing, executing and managing a broad range of REMS programs across many therapeutic areas. Dedicated to patient safety, our staff proactively tracks risk-management-related regulatory, legislative and market concerns, keeping us ahead of safety issues. Since 1998, we have developed efficient, cost-effective product development solutions, tailored to our clients’ needs.
Further Resources From the Amarex Team
Insights and Expertise
White Paper: Understanding Adaptive Designs for Clinical Trials
About the Authors
Deborah Cole, Marketing Associate, Amarex Clinical Research, LLC, an NSF company
Shide Badri, Safety and Pharmacovigilance Professional
1 Balian, J. D., Wherry, J. C., Malhotra, R., & Perentesis, V. (2010). Roadmap to risk evaluation and mitigation strategies (REMS) success. Therapeutic advances in drug safety, 1(1), 21–38. https://doi.org/10.1177/2042098610381419
2 U.S. Food and Drug Administration. Center for Drug Evaluation and Research. (2016) Background Materials for REMS Standardization and Evaluation Public Meeting. Retrieved from https://www.fda.gov/media/86199/download
3 Lippmann, E. (2017). FDA, CDER, Office of Regulatory Policy. Risk Evaluation and Mitigation Strategies (REMS) [PowerPoint slides]. Retrieved from https://www.fda.gov/media/105565/download
4 U. S. Food and Drug Administration. Center for Drug Evaluation and Research. (2019). Risk Evaluation and Mitigation Strategies: Modifications and Revisions. Guidance for Industry. Retrieved from https://www.fda.gov/media/128651/download
5 U. S. Food and Drug Administration. Center for Drug Evaluation and Research. (2020). Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency. Guidance for Industry and Healthcare Professionals. Retrieved from https://www.fda.gov/media/136317/download